AG真人官方

Capital International Investors reports beneficial ownership of 23,111,998 shares of Royalty Pharma plc, representing 5.5% of the approximately 421,370,657 shares believed outstanding. CII is deemed the beneficial owner through its investment management entities and holds sole voting power for 23,006,820 shares and sole dispositive power for 23,111,998 shares. The filing is a Schedule 13G and the reporting person is classified as an investment adviser (IA). The statement certifies the position is held in the ordinary course of business and was not acquired to change or influence control of the issuer.

Gregory Norden, a director of Royalty Pharma plc (RPRX), reported a non-cash exchange and a subsequent sale of Class A ordinary shares on Form 4. On 08/08/2025 he received 144,660 Class A shares in exchange for limited partnership interests in RPI US Partners 2019, LP under an Amended and Restated Exchange Agreement, increasing his reported direct holdings to 228,348 shares prior to any sale. On 08/11/2025 he sold 33,500 shares at a weighted average price of $36.2313 per share (reported range $36.10鈥�$36.40), reducing his direct ownership to 194,848 shares. The Form 4 was signed by an attorney-in-fact.

Royalty Pharma plc submitted a Form 144 proposing the sale of 33,500 Class A ordinary shares through Merrill Lynch on NASDAQ, with an approximate sale date of 08/11/2025. The filing lists an aggregate market value of $1,213,747.00 and 432,293,050 shares outstanding, so the proposed block represents a very small fraction of the company.

The shares were acquired on 04/13/2015 in an exchange of limited partnership interests from Royalty Pharma plc, with cash payment recorded. The filer reports no securities sold in the past three months and includes the standard representation that no material nonpublic information is known.

Pablo G. Legorreta, CEO and Chairman of Royalty Pharma plc, filed a Form 4 reporting an exempt acquisition on 08/06/2025 of 21,901 Class A Ordinary Shares at $0 in connection with settlement of Equity Performance Awards pursuant to Rule 16b-3. The transaction is recorded as an exempt award settlement and increases the reporting persons direct holdings.

The filing itemizes extensive indirect beneficial ownership through entities, trusts and family members with specific share counts such as Legorreta Investments LLC: 460,139, Legorreta Children 2002 Trust: 1,040,410, GST-Exempt Legorreta 2012 Family Trust: 901,590 and Legorreta 2023 SR Trust: 600,000, among others.

The form also discloses LP interests in RPI US Partners 2019, LP that are exchangeable under the Amended and Restated Exchange Agreement into Class A Ordinary Shares for no additional value; entries include a reported change dated 08/08/2025 listing 60,000 LP interests (noted as representing 600,000 Class A Ordinary Shares) and larger RPI US LP interest amounts shown for related entities.

Terrance P. Coyne, EVP & CFO of Royalty Pharma plc (RPRX), reported an exempt acquisition on 08/06/2025 of 3,696 Class A Ordinary Shares in connection with the settlement of Equity Performance Awards. The filing shows the award settlement with a $0 price and cites the acquisition as exempt under Rule 16b-3.

The Form 4 shows the reporting person beneficially owned 52,342 Class A Ordinary Shares following the reported transaction, held indirectly through TPC RP EPA1 LLC. The filing also discloses additional indirect holdings including 790,000 shares held by TPC RP 2021, LLC, IRA and spouse accounts, and a reported disposal of 1,500 shares. The form was signed by attorney-in-fact on 08/08/2025.

Royalty Pharma's Form 4 reports that the reporting person listed as "Lloyd George W." (identified as EVP, Investments & CLO) acquired 3,696 Class A Ordinary Shares on 08/06/2025 through the settlement of Equity Performance Awards, an exempt acquisition pursuant to Rule 16b-3. The filing also records a disposition of 3,000 Class A shares and shows multiple indirect holdings held by several related entities and the reporting person's spouse.

Table II discloses limited partnership interests in RPI US Partners 2019, LP that are exchangeable: each RPI US LP Interest may be exchanged for ten Class B Interests, and each Class B Interest will be exchanged for one Class A Ordinary Share, meaning each LP interest converts into ten Class A shares. The filing lists underlying Class A equivalents of 581,730, 2,917,390, 2,726,720, 1,301,480 and 85,000 related to those interests. The form was signed by an attorney-in-fact on 08/08/2025.

Christopher Hite, EVP & Vice Chairman of Royalty Pharma plc (RPRX), reported insider transactions on Form 4. The filing records an exempt acquisition of 3,696 Class A ordinary shares on 08/06/2025 in connection with the settlement of Equity Performance Awards under Rule 16b-3, recorded with a price of $0. The form also shows a reported disposition of 70,000 Class A ordinary shares (marked as a sale).

After the reported activity, the total beneficial ownership is reported as 652,342 shares, held indirectly through SCH Investment Partners LLC. The filing was signed by an attorney-in-fact on behalf of Mr. Hite.

Marshall Urist, EVP, Research & Investments at Royalty Pharma plc (RPRX), reported an exempt acquisition of 2,772 Class A Ordinary Shares in connection with settlement of Equity Performance Awards on 08/06/2025 at $0 per share. Following the reported transaction, the filing shows 39,256 Class A shares beneficially owned directly by the reporting person and additional indirect holdings of 46,667 shares through Sandy Lamm LLC and 19,020 shares through an IRA.

The filing also records acquisition of 3,000 limited partnership interests in RPI US Partners 2019, LP (reported 08/08/2025), which are convertible at the holder's option into 30,000 Class A Ordinary Shares (each LP interest convertible into ten Class B Interests, each Class B exchangeable for one Class A share) for no additional value. Table II indicates 263,412 Class A shares indirectly beneficially owned by Sandy Lamm LLC following the derivative interests reported. The acquisition is characterized as exempt under Rule 16b-3.